Gotowa bibliografia na temat „BRCA genes”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „BRCA genes”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "BRCA genes"
Zhang, Yinuo. "BRCA1, BRCA2 and primary ovarian insufficiency". E3S Web of Conferences 165 (2020): 05009. http://dx.doi.org/10.1051/e3sconf/202016505009.
Pełny tekst źródłaMcNevin, Ciara S., Karen Cadoo, Anne-Marie Baird, Pierre Murchan, Orla Sheils, Ray McDermott i Stephen Finn. "Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer". Cancers 13, nr 22 (14.11.2021): 5697. http://dx.doi.org/10.3390/cancers13225697.
Pełny tekst źródłaSchwartz, Zachary Phillip, Mae Zakhour, Andrew John Li, Christine S. Walsh, Bj Rimel, Monica Alvarado, Scott E. Lentz i Ilana Cass. "Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 1547. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1547.
Pełny tekst źródłaSahnane, Nora, Ileana Carnevali, Giorgio Formenti, Jvan Casarin, Sofia Facchi, Raffaella Bombelli, Eleonora Di Lauro i in. "BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor". International Journal of Molecular Sciences 21, nr 24 (19.12.2020): 9708. http://dx.doi.org/10.3390/ijms21249708.
Pełny tekst źródłaIncorvaia, Lorena, Chiara Brando, Alessandro Perez, Marco Bono, Daniela Cancelliere, Alessia Pivetti, Nadia Barraco i in. "Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients." Journal of Clinical Oncology 41, nr 16_suppl (1.06.2023): 10592. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10592.
Pełny tekst źródłaЖурман, В. Н., Н. Г. Плехова i М. Л. Филипенко. "Mutational Status of BRCA Genes in Ovarian Cancer". Евразийский онкологический журнал, nr 2 (16.08.2022): 118–25. http://dx.doi.org/10.34883/pi.2022.10.2.016.
Pełny tekst źródłaMcNevin, Ciara S., Karen Cadoo, Anne-Marie Baird, Stephen P. Finn i Ray McDermott. "PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures". Cancers 14, nr 19 (29.09.2022): 4751. http://dx.doi.org/10.3390/cancers14194751.
Pełny tekst źródłaMeireles, Pedro Antunes, Catarina Bexiga, Sofia Fragoso, Sidónia Santos, Teresa Duarte i Fátima Vaz. "Abstract PO3-08-03: Comparing prognosis for BRCA1, BRCA2 and non-BRCA breast cancer". Cancer Research 84, nr 9_Supplement (2.05.2024): PO3–08–03—PO3–08–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-08-03.
Pełny tekst źródłaBrankovic-Magic, Mirjana, Jelena Dobricic, Radmila Jankovic, Irene Konstantopoulou, Drakoulis Yannoukakos i Sinisa Radulovic. "Identifying and testing for hereditary susceptibility to breast/ovarian cancer in Serbia: Where are we now?" Archive of Oncology 14, nr 3-4 (2006): 131–35. http://dx.doi.org/10.2298/aoo0604131b.
Pełny tekst źródłaFoglietta, Jennifer, Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, Maria Sole Reda, Antonella Al-Refaie, Francesca Romana Tofanetti i in. "Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study". Genes 11, nr 8 (12.08.2020): 925. http://dx.doi.org/10.3390/genes11080925.
Pełny tekst źródłaRozprawy doktorskie na temat "BRCA genes"
Mavaddat, Nasim. "Risk modelling in BRCA1 and BRCA2 mutation carriers". Thesis, University of Cambridge, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.610839.
Pełny tekst źródłaEwald, Ingrid Petroni. "Caracterização de um grupo de pacientes em risco para câncer de mama e ovário hereditários quanto a presença e frequência de rearranjos gênicos em BRCA". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2012. http://hdl.handle.net/10183/53154.
Pełny tekst źródłaBreast cancer is one of the most common malignancies affecting women worldwide. In Brazil, the State of Rio Grande do Sul has incidence rates and mortality from breast cancer are among the largest in the country. Approximately 5-10% of the cases are caused by germline mutations in predisposing genes including BRCA1 and BRCA2 are associated with the syndrome of breast and ovarian cancer Hereditary (Hereditary Breast and Ovarian Cancer Syndrome or HBOC, OMIM # 114480). The identification of inherited cases of breast cancer is important because affected individuals have cumulative risk life much higher than the population for developing cancer because of an affected family may also be at risk because there are measures of intensive screening and preventive interventions that can significantly decrease the risk of cancer in mutation carriers. The molecular diagnosis of HBOC syndrome is laborious and expensive due to the molecular heterogeneity of the disease. Families that have characteristics indicative of a cancer predisposition syndrome of hereditary breast and ovarian cancers, but are negative for mutations in BRCA1/2 have been tested for large rearrangements because these abnormalities have been identified as accounting for at least 10 % of all cases HBOC identifiable mutation, including large deletions or duplications. A recent study from Portugal, the founder showed that a rearrangement in exon 3 of BRCA2 occurs in 8% of HBOC families of the north. The objectives of this work included the verification of the frequency and characterization of gene rearrangements in BRCA1 and BRCA2 genes, including c.156_157insAlu founder mutation in exon 3 of BRCA2 mutations in Brazilian families at high risk for HBOC syndrome. In a group of 145 individuals at risk unrelated traced to c.156_157insAlu founder mutation in exon 3 of 3 found BRCA2 mutation carriers (prevalence 2%). In a group of 145 individuals at risk unrelated screened for gene rearrangements in BRCA1 and BRCA2 by the technique of MLPA (multiplex ligationdependent probe amplification) identified four carriers of germline mutation, and two of the mutation in a gene rearrangement in the gene BRCA1 (1.4%) involving Alu sequences. Gene rearrangements in BRCA1 and BRCA2 account for a portion of HBOC mutations in Brazilian families. This study, involving a large series of families with HBOC syndrome phenotype, no new rearrangements identified founders, however, showed the presence of rearrangements in both BRCA1 and BRCA2, reiterating the importance of active search for these changes, which hardly are identified by conventional techniques of gene sequencing. The technique of MLPA protocol associated with a specific mutation detection founder Portuguese c.156_157insAlu strategy can be used as initial screening for mutations in families with Brazilian syndrome. The results presented here, however, indicate mutations that will be identified in less than 10% of the cases using this strategy.
Ramirez, Christina J. "BRCA genes : conserved regions and the potential effect of missense changes /". Thesis, Connect to this title online; UW restricted, 2005. http://hdl.handle.net/1773/5052.
Pełny tekst źródłaTurk, Casey M. "Paralemmin splice variants and mRNA and protein expression in breast cancers". Connect to this title, 2008. http://scholarworks.umass.edu/theses/194/.
Pełny tekst źródłaWarren, Curtis R. "Linker region of the BRCA2 protein increases chemoresistance to cisplatin: Screen for the characterization of cancer-associated variants". Access to citation, abstract and download form provided by ProQuest Information and Learning Company; downloadable PDF file, 84 p, 2009. http://proquest.umi.com/pqdweb?did=1885607671&sid=3&Fmt=2&clientId=8331&RQT=309&VName=PQD.
Pełny tekst źródłaSolyom, S. (Szilvia). "BRCA/Fanconi anemia pathway genes in hereditary predisposition to breast cancer". Doctoral thesis, Oulun yliopisto, 2011. http://urn.fi/urn:isbn:9789514294099.
Pełny tekst źródłaTiivistelmä BRCA1 ja BRCA2 ovat kaksi tärkeintä perinnöllisen rinta- ja munasarjasyövän alttiusgeeniä. Niissä esiintyvät ituradan muutokset selittävät kuitenkin vain noin 20 % familiaalisista rintasyöpätapauksista. Suurin osa alttiusgeeneistä on edelleen tunnistamatta ja näitä tekijöitä etsitään aktiivisesti. Tämän tutkimuksen tarkoituksena on ollut tunnistaa uusia alttiustekijöitä toisiinsa läheisesti liittyviltä BRCA/Fanconin anemia (FA) signaalinsiirtoreiteiltä. Viisi kandidaattigeeniä - MERIT40, ABRAXAS, BRIP1, CHK1 ja FANCA – kartoitettiin mutaatioiden suhteen suomalaisissa rintasyöpäperheissä käyttämällä konformaatiosensitiivistä geelielektroforeesia ja sekvensointia, tai multiplex ligation-dependent probe amplification- menetelmää. MERIT40-geenissä havaittiin useita aikaisemmin raportoimattomia nukleotidimuutoksia, mutta yhdenkään niistä ei havaittu liittyvän rintasyöpäalttiuteen. MERIT40-geenimuutosten mahdollista yhteyttä rintasyöpäalttiuteen ei ole tutkittu aikaisemmin. ABRAXAS-geenissä havaittiin missense-mutaatio (c.1082G>A, joka johtaa Arg361Gln aminohappokorvautumiseen) kolmessa pohjoissuomalaisessa rintasyöpäperheessä (3/125, 2.4 %). Muutosta ei havaittu terveissä kontrolleissa (N=867), ja ero mutaation esiintyvyydessä familiaalisten rintasyöpätapausten ja terveiden kontrollien välillä oli tilastollisesti merkitsevä (p=0.002). ABRAXAS c.1082G>A-muutos on todennäköisesti patogeeninen, sillä kyseinen aminohappopaikka on evolutiivisesti konservoitunut ja sijaitsee todennäköisellä tumaanohjaussignaalialueella. Funktionaaliset kokeet osoittivat, että mutatoitunut proteiinituote lokalisoitui villityypin proteiinia heikommin tumaan ja sen ohjautuminen DNA-vaurioalueille oli puutteellista. BRIP1- (FANCJ) ja CHK1-geeneistä etsittiin laajoja genomisia uudelleenjärjestelyjä, mutta niitä ei havaittu. Näin ollen kyseisillä muutoksilla ei ole merkittävää roolia perinnöllisessä rintasyöpäalttiudessa suomalaisessa väestössä. FANCA-geenissä havaittiin laaja heterotsygoottinen deleetio yhdessä tutkitusta 100 rintasyöpäperheestä. Deleetio poistaa geenin promoottorialueen lisäksi sen 12 ensimmäistä eksonia. Deleetioalleelia ei havaittu terveissä kontrolleissa, joten se mahdollisesti liittyy perinnölliseen rintasyöpäalttiuteen. Tutkimus on ensimmäinen, jossa raportoidaan laaja genominen deleetio FA-signaalinsiirtoreitin ylävirran geenissä familiaalisessa rintasyövässä
Mozersky, J. "'Ashkenazi mutations' and the BRCA genes : genetics, disease and Jewish identity". Thesis, University College London (University of London), 2009. http://discovery.ucl.ac.uk/19035/.
Pełny tekst źródłaSkoulidis, Ferdinandos. "Models of pancreatic carcinogenesis associated with inactivation of the BRCA2 breast cancer susceptibility gene". Thesis, University of Cambridge, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.609916.
Pełny tekst źródłaPRESNEAU, NADEGE. "Recherche de mutations constitutionnelles dans les genes de predispositions hereditaires aux cancers du sein et/ou de l'ovaire : brca-1, brca-2. recherche de nouveaux genes suppresseurs de tumeur impliques dans l'oncogenese mammaire". Clermont-Ferrand 2, 1999. http://www.theses.fr/1999CLF21122.
Pełny tekst źródłaFerlatte, Christy. "Patient preferences for an appropriate time for cancer genetic counseling and BRCA testing for women diagnosed with breast cancer". Waltham, Mass. : Brandeis University, 2009. http://dcoll.brandeis.edu/handle/10192/23193.
Pełny tekst źródłaKsiążki na temat "BRCA genes"
Gabriel, Sarah. Eating pomegranates: A memoir of mothers, daughters, and the BRCA gene. New York: Scribner, 2009.
Znajdź pełny tekst źródłaHerrlinger, Karolina Anna. Die Patentierung von Krankheitsgenen: Dargestellt am Beispiel der Patentierung der Brustkrebsgene BRCA 1 und BRCA 2. Köln: Heymanns, 2005.
Znajdź pełny tekst źródłaGabriel, Sarah. Eating pomegranates: A memoir of mothers, daughters and genes. Rearsby: Clipper Large Print, 2010.
Znajdź pełny tekst źródłaauthor, Gosline Diana, i Smith Diana author, red. Deleterious: A Mutant Gene Zine. Portland, OR: the authors, 2015.
Znajdź pełny tekst źródłaGabriel, Sarah. Eating pomegranates: A memoir of mothers, daughters, and the BRCA gene. New York: Scribner, 2010.
Znajdź pełny tekst źródłaH, Lu Karen, red. Hereditary gynecologic cancer: Risk, prevention, and management. New York: Informa Healthcare, 2008.
Znajdź pełny tekst źródłaservice), SpringerLink (Online, red. The Role of Genetics in Breast and Reproductive Cancers. New York, NY: Springer Science+Business Media, LLC, 2010.
Znajdź pełny tekst źródłaSimons, Amanda Marie. Biochemical functions of BRCA1 protein complexes. 2006.
Znajdź pełny tekst źródłaBreast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of Brca. Routledge, 2014.
Znajdź pełny tekst źródłaGIBBON, SAHRA, Jessica Mozersky, Andrea zur Nieden, Galen Joseph i Sonja Palfner. Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA. Taylor & Francis Group, 2014.
Znajdź pełny tekst źródłaCzęści książek na temat "BRCA genes"
Golen, Kenneth L., i Sofia D. Merajver. "Structure and Function of BRCA Genes". W Endocrine Oncology, 337–51. Totowa, NJ: Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-223-4_18.
Pełny tekst źródłaHan, Sang-Ah, i Sung-Won Kim. "BRCA and Breast Cancer-Related High-Penetrance Genes". W Advances in Experimental Medicine and Biology, 473–90. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-32-9620-6_25.
Pełny tekst źródłaZhu, Yining, Ethan Sun i Yongsheng Bai. "Dissecting Biological Functions for BRCA Genes and Their Targeting MicroRNAs Within Eight Clusters". W Big Data – BigData 2020, 247–51. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-59612-5_18.
Pełny tekst źródłaVenkitaraman, Ashok R. "Breast Cancer Genes BRCA1 and BRCA2". W Encyclopedia of Cancer, 510–13. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_718.
Pełny tekst źródłaSaleem, Mohamed, Mohd Bazli Ghazali, Md Azlan Mohamed Abdul Wahab, Narazah Mohd Yusoff, Hakimah Mahsin, Ch’ng Ewe Seng, Imran Abdul Khalid, Mohd Nor Gohar Rahman i Badrul Hisham Yahaya. "The BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients". W Advances in Experimental Medicine and Biology, 1–12. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/5584_2018_147.
Pełny tekst źródłaTavtigian, Sean V. "Unclassified Variants in the Breast Cancer Susceptibility Genes BRCA1 and BRCA2". W The Role of Genetics in Breast and Reproductive Cancers, 49–73. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-1-4419-0477-5_3.
Pełny tekst źródłaHampl, M., J. Hampl, St Frank, M. Hahn, M. Nagel, D. Ockert, G. Schackert, H. D. Saeger i H. K. Schackert. "Allelverlust von prädisponierenden Genen (BRCA1, BRCA2, AT, p53) bei Mammakarzinomen und deren Metastasen". W Chirurgisches Forum ’96 fur experimentelle und klinische Forschung, 201–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-80138-9_41.
Pełny tekst źródłaMansoor, Sheikh, Usma Manzoor, Aabid Mustafa Koul, Shahid M. Baba, Ina Amin, Iqra Anwar, Qurat ul Aein i Arshad A. Pandith. "Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer". W Breast Cancer: From Bench to Personalized Medicine, 87–112. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-0197-3_5.
Pełny tekst źródłaPearman, Timothy. "Psychological Implications of Testing Positive for the BRCA Gene". W Management of the Patient at High Risk for Breast Cancer, 155–60. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5891-3_11.
Pełny tekst źródłaEißing, Tabea. "Vorbeugen und Verhindern. Über den vereindeutigenden Umgang mit Unsicherheit bei Frauen mit einer BRCA-Mutation". W Die Regierung der Gene, 57–82. Wiesbaden: Springer Fachmedien Wiesbaden, 2015. http://dx.doi.org/10.1007/978-3-658-09651-9_3.
Pełny tekst źródłaStreszczenia konferencji na temat "BRCA genes"
Farias, Stephanie Freire Soares de, Graziela Gama da Conceição Gomes, Biatriz Costa Diniz, CAIO DE BRITO MATOS i MARCOS VINÍCIUS SOUZA DE ALMEIDA. "GENES RELACIONADOS AO CÂNCER DE MAMA: UM ESTUDO ACERCA DOS ONCOGENES". W I Congresso Nacional de Pesquisas e Estudos Genéticos On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/geneticon/9136.
Pełny tekst źródłaGomes, Marina Macedo, i Kamylle Cynnara Tavares da Silva. "MUTAÇÃO DOS GENES BRCA1 E BRCA2 COMO ETIOLOGIA GENÉTICA DO CÂNCER DE MAMA". W XXVII Semana de Biomedicina Inovação e Ciência. Editora IME, 2021. http://dx.doi.org/10.51161/9786588884119/8.
Pełny tekst źródłaCarvalho, Débora Medeiros de, Kamila Bezerra Fernandes Diocesano, Sabas Carlos Vieira, Maysa Gabriela Costa Cruz, Fernanda Jorge Martins, Camila Holanda de Sousa i Nívya Emanuele Vilarinda dos Santos. "Epidemiological and histo-molecular profile of patients with breast cancer who underwent genetic testing at a tertiary clinic in northeastern Brazil". W Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1069.
Pełny tekst źródłaMolokov, A. Yu, P. A. Gervas i N. V. Cherdyntseva. "THE IDENTIFICATION BY EXOME SEQUENCING OF CANDIDATE BREAST CANCER GENES IN BRCA-NEGATIVE TUVAN PATIENTS". W X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-349.
Pełny tekst źródłaGoveia, Rebeca Mota, Paula Francinete Faustino Silva, Thais Bomfim Teixeira, Isabela Gasparini Arraes, Ruffo Freitas-Júnior i Elisângela Paula Silveira Lacerda. "ANALYSIS OF PATHOGENIC AND UNCERTAIN SIGNIFICANCE VARIANTS IN NINE GENES OF THE BRCA1-MEDIATED HOMOLOGOUS RECOMBINATION PATHWAY IN PATIENTS WITH SUSPECTED HEREDITARY BREAST AND OVARIAN CANCER SYNDROME IN CENTRAL BRAZIL." W Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1038.
Pełny tekst źródłaHeinzen, Rebeca Neves, Maria Eduarda Meyer, Liliane Raupp Gomes Pizatto i Adriana Magalhães de Oliveira Freitas. "PREVALENCE OF VARIANTS OF UNCERTAIN SIGNIFICANCE IN TESTS REQUESTED FOR BREAST CANCER PATIENTS IN A PRIVATE SERVICE". W Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1049.
Pełny tekst źródłaPaixão, Daniele, Giovana Tardin Torrezan, Karina Miranda Santiago, Maria Nirvana Formiga, Emmanuel Dias Neto, Israel Tojal da Silva, Paz Polak i Dirce Maria Carraro. "MULTIGENE PANEL TESTING FOR BREAST CANCER PREDISPOSITION IN BRAZILIAN PATIENTS". W Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2016.
Pełny tekst źródłaBrianese, Rafael Canfield, Karina Miranda Santiago, Giovana Tardin Torrezan, Marina de Brot, José Claudio Casali da Rocha, Fabiana Baroni Alves Makdissi i Dirce Maria Carraro. "MULTIGENE GERMLINE NGS TESTING IN TRIPLENEGATIVE BREAST CANCER (TNBC)". W Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2006.
Pełny tekst źródłaAmorim, Ísis Salviano Soares de, Priscyanne Barreto Siqueira, Mariana Moreno de Sousa Rodrigues i Andre Luiz Mencalha. "GENOMIC AND CLINICAL DATA ANALYSIS OF APE1 PROTEIN, BREAST CANCER STEM CELL PHENOTYPE, AND HYPOXIC TUMOR MICROENVIRONMENT". W Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2004.
Pełny tekst źródłaNero, Camilla, Francesca Ciccarone, Luca Boldrini, Jacopo Lenkowicz, Huong Elena Tran, Maria Teresa Giudice, Francesca Sillano i in. "#119 Prediction of germline brca 1/2 genes pathogenetic variants from healthy ovaries ultrasound images: radiogenomics as an innovative tool to prevent BRCA-related cancers". W ESGO 2023 Congress. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/ijgc-2023-esgo.868.
Pełny tekst źródłaRaporty organizacyjne na temat "BRCA genes"
Elledge, Stephen J. Identification of Genes Required for the Survival of BRCA 1-/- Cells. Fort Belvoir, VA: Defense Technical Information Center, luty 2010. http://dx.doi.org/10.21236/ada523167.
Pełny tekst źródłaElledge, Stephen. Identification of Genes Required for the Survival of BRCA 1-/- Cells. Fort Belvoir, VA: Defense Technical Information Center, luty 2011. http://dx.doi.org/10.21236/ada551382.
Pełny tekst źródłaVerma, Inder, i Quan Zhu. A Genetic Screen for Genes Involved in BRCA 1 Tumor Suppressor Function. Fort Belvoir, VA: Defense Technical Information Center, marzec 2007. http://dx.doi.org/10.21236/ada469482.
Pełny tekst źródłaLee, Cheng-Chi. Cloning Human Chromosome 17 Genes: Candidate Genes for BRCA1. Fort Belvoir, VA: Defense Technical Information Center, październik 1998. http://dx.doi.org/10.21236/ada361576.
Pełny tekst źródłaRauscher, Frank J. Characterization of Two Proteins Which Interact With the BRCA 1 Gene. Fort Belvoir, VA: Defense Technical Information Center, czerwiec 2001. http://dx.doi.org/10.21236/ada406224.
Pełny tekst źródłaLobenhofar, Edward K., i Jeff Marks. Characterization of the Breast Cancer Susceptibility Gene BRCA2. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2000. http://dx.doi.org/10.21236/ada395289.
Pełny tekst źródłaLynch, Dennis M. Cell Cycle Analysis of the BRCA1 Gene Product. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2000. http://dx.doi.org/10.21236/ada405841.
Pełny tekst źródłaWang, Yingcai, i Stuart Aaronson. Functional Analysis of Breast Cancer Susceptibility Gene BRCA2. Fort Belvoir, VA: Defense Technical Information Center, sierpień 1999. http://dx.doi.org/10.21236/ada391163.
Pełny tekst źródłaLivingston, David M., i Dennis Lynch. Cell Cycle Analysis of the BRCA1 Gene Product. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 1999. http://dx.doi.org/10.21236/ada377810.
Pełny tekst źródłaKing, Mary-Claire, i Warren Winkelstein Jr. Genetic Alterations in Familial Breast Cancer: Mapping and Cloning Genes Other than BRCA1. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 1996. http://dx.doi.org/10.21236/ada328004.
Pełny tekst źródła